Content area

|
|

Knogletæthedsmåling og biomarkører til monitorering af osteoporosebehandling

Forfatter(e)

Søren Bønløkke Pedersen* 1, 2, Michael Schønemann Rand* 1, 2, Pia A. Eiken3, 4, Niklas Rye Jørgensen1, 2

1) Odense Patient Data Explorative Network, Klinisk Institut, Syddansk Universitet 2) Klinisk Biokemisk Afdeling, Rigshospitalet, Glostrup 3) Kardiologisk, Nefrologisk, Endokrinologisk Afdeling, Nordsjællands Hospital, Hillerød 4) Institut for Klinisk Medicin, Københavns Universitet Ugeskr Læger 2018;180:V12170926

Reference: 
Ugeskr Læger 2018;180:V12170926
Blad nummer: 
Sidetal: 
2-6
Monitoring anti-osteoporotic therapy: bone mineral density or markers of bone turnover

This review discusses two methods of monitoring the effect of anti-osteoporotic treatment: bone mineral density (BMD) and bone turnover markers (BTMs). Both monitoring strategies are to some extent able to predict the treatment-induced change in risk of fracture. The use of BMD is commonplace, and clinicians are experienced in the interpretation of data. The use and knowledge of BTMs among clinicians is limited, but it allows for early testing while being practical and cheap. Further knowledge and implementation of BTMs in the clinical practice may improve the monitoring capabilities.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Eskild Boeskov | 23/01
6 kommentarer
af Pal Bela Szecsi | 20/01
2 kommentarer
af Peter Søndergaard | 18/01
3 kommentarer
af Mads Henrik Koch Hansen | 16/01
2 kommentarer
af Lars Guttorm | 14/01
5 kommentarer
af Morten Ellemose Gulev | 14/01
4 kommentarer
af Henning Damgaard Laugesen | 14/01
1 Kommentar